Deutsche Bank AG Has $11.36 Million Holdings in NeuroPace, Inc. $NPCE

Key Points

• Deutsche Bank AG increased its stake in NeuroPace, Inc. by 124.0% in the first quarter, holding approximately 2.82% of the company valued at $11,359,000.
• Analysts are optimistic about NeuroPace, with several firms setting a "buy" rating and average price targets ranging from $15.00 to $18.00.
• Despite achieving revenues of $23.52 million in the last quarter, NeuroPace reported a loss of ($0.26) earnings per share, missing analyst expectations.

Deutsche Bank AG lifted its stake in NeuroPace, Inc. (NASDAQ:NPCE - Free Report) by 124.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 924,274 shares of the company's stock after buying an additional 511,662 shares during the period. Deutsche Bank AG owned approximately 2.82% of NeuroPace worth $11,359,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in NPCE. BNP Paribas Financial Markets bought a new stake in shares of NeuroPace in the fourth quarter valued at approximately $29,000. GAMMA Investing LLC bought a new stake in shares of NeuroPace in the first quarter valued at approximately $53,000. Wells Fargo & Company MN boosted its stake in shares of NeuroPace by 54.2% in the fourth quarter. Wells Fargo & Company MN now owns 6,483 shares of the company's stock valued at $73,000 after buying an additional 2,279 shares during the period. MetLife Investment Management LLC bought a new stake in shares of NeuroPace in the fourth quarter valued at approximately $103,000. Finally, Birchview Capital LP bought a new stake in shares of NeuroPace in the fourth quarter valued at approximately $112,000. 78.83% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently issued reports on NPCE. HC Wainwright began coverage on NeuroPace in a research note on Wednesday, May 28th. They issued a "buy" rating and a $18.00 price target for the company. JPMorgan Chase & Co. increased their price target on shares of NeuroPace from $14.00 to $16.00 and gave the stock an "overweight" rating in a research report on Wednesday, May 14th. Wells Fargo & Company reduced their price target on shares of NeuroPace from $17.00 to $15.00 and set an "overweight" rating on the stock in a research report on Wednesday, August 13th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $17.00 price target on shares of NeuroPace in a research report on Wednesday, May 14th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, NeuroPace has a consensus rating of "Buy" and an average price target of $16.60.

NeuroPace Price Performance

NeuroPace stock traded down $0.09 during mid-day trading on Monday, reaching $8.47. The company had a trading volume of 127,580 shares, compared to its average volume of 275,374. The business has a fifty day simple moving average of $9.91 and a 200 day simple moving average of $11.70. The company has a market cap of $280.19 million, a P/E ratio of -10.08 and a beta of 1.89. The company has a current ratio of 5.47, a quick ratio of 4.51 and a debt-to-equity ratio of 3.02. NeuroPace, Inc. has a fifty-two week low of $5.45 and a fifty-two week high of $18.98.

NeuroPace (NASDAQ:NPCE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The company had revenue of $23.52 million for the quarter, compared to analyst estimates of $23.08 million. NeuroPace had a negative return on equity of 168.61% and a negative net margin of 29.29%. On average, equities research analysts predict that NeuroPace, Inc. will post -1 earnings per share for the current year.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.